(PharmaNewsWire.Com, May 23, 2017 ) "Diglyceride Acyltransferase 1 (DGAT-1) Inhibitors-Pipeline Insights, 2016", report provides in depth insights on the pipeline drugs and their development activities around the Diglyceride Acyltransferase 1 (DGAT-1) Inhibitors. The Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Diglyceride Acyltransferase 1 (DGAT-1) Inhibitors. Report also assesses the Diglyceride Acyltransferase 1 (DGAT-1) Inhibitors therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including: